These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 37607644)
1. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study. Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644 [TBL] [Abstract][Full Text] [Related]
2. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease. Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972 [TBL] [Abstract][Full Text] [Related]
3. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911 [TBL] [Abstract][Full Text] [Related]
5. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785 [TBL] [Abstract][Full Text] [Related]
13. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115. Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321 [TBL] [Abstract][Full Text] [Related]
14. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787 [TBL] [Abstract][Full Text] [Related]
15. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Quillen K; Seldin DC; Finn KT; Sanchorawala V Bone Marrow Transplant; 2011 Jul; 46(7):976-80. PubMed ID: 20956955 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Girnius S; Seldin DC; Meier-Ewert HK; Sloan JM; Quillen K; Ruberg FL; Berk JL; Doros G; Sanchorawala V Bone Marrow Transplant; 2014 Mar; 49(3):434-9. PubMed ID: 24317129 [TBL] [Abstract][Full Text] [Related]
17. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series. Lee SY; Sanchorawala V; Seldin DC; Mark Sloan J; Andrea N; Quillen K Amyloid; 2014 Sep; 21(3):149-53. PubMed ID: 24779777 [TBL] [Abstract][Full Text] [Related]
18. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis. Lee SY; Meehan RS; Seldin DC; Sloan JM; Quillen K; Shelton A; Brauneis D; Sanchorawala V Bone Marrow Transplant; 2016 Oct; 51(10):1318-1322. PubMed ID: 27183092 [TBL] [Abstract][Full Text] [Related]
19. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation. Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954 [TBL] [Abstract][Full Text] [Related]
20. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]